5,005
edits
Main Page: Difference between revisions
From W8MD weight loss and sleep centers
no edit summary
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
[[File:W8MD-Team.jpg|800px|left]] | |||
The W8MD' [[W8MD_Weight_Loss,_Sleep_and_Medspa|physician weight loss]] program is a clinically proven, evidence-based program that helps patients [[lose weight]] and maintain the weight with an ongoing maintenance plan for [[medical-weight-loss|adults]] and [[childhood obesity|children]]. [[W8MD_Weight_Loss,_Sleep_and_Medspa|Learn more...]] | The W8MD' [[W8MD_Weight_Loss,_Sleep_and_Medspa|physician weight loss]] program is a clinically proven, evidence-based program that helps patients [[lose weight]] and maintain the weight with an ongoing maintenance plan for [[medical-weight-loss|adults]] and [[childhood obesity|children]]. [[W8MD_Weight_Loss,_Sleep_and_Medspa|Learn more...]] | ||
==Zepbound / Mounjaro (Tirzepatide) weight loss == | |||
[[Tirzepatide]], available as [[Zepbound]] and [[Mounjaro]], is a weekly injection that helps control blood sugar levels and was approved for use in treating type 2 diabetes by the FDA in May 2022. Distinguished from drugs such as [[Ozempic]] and [[Wegovy]] both of which have [[Semaglutide]], [[Zepbound]], [[Mounjaro]] with active ingredient of [[Tirzepatide]] is a combination of a glucagon-like peptide-1 (GLP-1) receptor agonist, used for diabetes and weight loss treatment, and a glucose-dependent insulinotropic polypeptide (GIP), a hormone that aids insulin release after eating. | |||
==Wegovy / Ozempic (Semaglutide) injections== | |||
Although it has yet to be approved by the FDA for [[weight loss]], some doctors, including '''W8MD weight loss physicians''', prescribe it for off-label use to help with weight loss in patients without type 2 diabetes. In fact, Mounjaro became so popular that it was listed by the FDA as one of nearly 200 drugs experiencing a supply shortage, along with [[Wegovy]], [[Ozempic]] (semaglutide), and [[Trulicity]] (dulaglutide), which are sometimes prescribed for off-label [[weight loss]] use. [[Mounjaro|Learn more...]] | |||
{|style="border-spacing:8px;margin:0px -8px" | {|style="border-spacing:8px;margin:0px -8px" | ||
|class="MainPageBG" style="width:55%;border:1px solid #cef2e4;background-color:#f5fffa;vertical-align:top;color:#000"| | |class="MainPageBG" style="width:55%;border:1px solid #cef2e4;background-color:#f5fffa;vertical-align:top;color:#000"| | ||
| Line 51: | Line 58: | ||
In October 2022, the Food and Drug Administration (FDA) granted Mounjaro, a diabetes drug, a fast-track designation for weight loss, leading to speculation that it will be approved for weight loss use this year due to its promising results in clinical trials. | In October 2022, the Food and Drug Administration (FDA) granted Mounjaro, a diabetes drug, a fast-track designation for weight loss, leading to speculation that it will be approved for weight loss use this year due to its promising results in clinical trials. | ||
[[File:Weight-loss-success-stories.jpeg|thumb|Weight loss success stories]] | [[File:Weight-loss-success-stories.jpeg|thumb|Weight loss success stories]] | ||
[[File:W8md-protein-bar.jpeg|thumb|Weight loss supplements]] | [[File:W8md-protein-bar.jpeg|thumb|Weight loss supplements]] | ||
==3 things wrong with our diet== | ==3 things wrong with our diet== | ||
